185 related articles for article (PubMed ID: 37015151)
1. Combined glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonism attenuates atherosclerosis severity in APOE*3-Leiden.CETP mice.
van Eenige R; Ying Z; Tramper N; Wiebing V; Siraj Z; de Boer JF; Lambooij JM; Guigas B; Qu H; Coskun T; Boon MR; Rensen PCN; Kooijman S
Atherosclerosis; 2023 May; 372():19-31. PubMed ID: 37015151
[TBL] [Abstract][Full Text] [Related]
2. Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice.
Ying Z; van Eenige R; Ge X; van Marwijk C; Lambooij JM; Guigas B; Giera M; de Boer JF; Coskun T; Qu H; Wang Y; Boon MR; Rensen PCN; Kooijman S
EBioMedicine; 2023 Jul; 93():104684. PubMed ID: 37379656
[TBL] [Abstract][Full Text] [Related]
3. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
[TBL] [Abstract][Full Text] [Related]
4. A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus.
Smith C; Patterson-Cross R; Woodward O; Lewis J; Chiarugi D; Merkle F; Gribble F; Reimann F; Adriaenssens A
Appetite; 2022 Jul; 174():106022. PubMed ID: 35430298
[TBL] [Abstract][Full Text] [Related]
5. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.
Zhou E; Li Z; Nakashima H; Choukoud A; Kooijman S; Berbée JFP; Rensen PCN; Wang Y
Pharmacol Res; 2021 May; 167():105524. PubMed ID: 33667684
[TBL] [Abstract][Full Text] [Related]
7. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.
Maida A; Lamont BJ; Cao X; Drucker DJ
Diabetologia; 2011 Feb; 54(2):339-49. PubMed ID: 20972533
[TBL] [Abstract][Full Text] [Related]
8. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.
Akindehin S; Liskiewicz A; Liskiewicz D; Bernecker M; Garcia-Caceres C; Drucker DJ; Finan B; Grandl G; Gutgesell R; Hofmann SM; Khalil A; Liu X; Cota P; Bakhti M; Czarnecki O; Bastidas-Ponce A; Lickert H; Kang L; Maity G; Novikoff A; Parlee S; Pathak E; Schriever SC; Sterr M; Ussar S; Zhang Q; DiMarchi R; Tschöp MH; Pfluger PT; Douros JD; Müller TD
Mol Metab; 2024 May; 83():101915. PubMed ID: 38492844
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis.
Hoeke G; Wang Y; van Dam AD; Mol IM; Gart E; Klop HG; van den Berg SM; Pieterman EH; Princen HMG; Groen AK; Rensen PCN; Berbée JFP; Boon MR
Atherosclerosis; 2017 Dec; 267():116-126. PubMed ID: 29121499
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice.
Parlevliet ET; Wang Y; Geerling JJ; Schröder-Van der Elst JP; Picha K; O'Neil K; Stojanovic-Susulic V; Ort T; Havekes LM; Romijn JA; Pijl H; Rensen PC
PLoS One; 2012; 7(11):e49152. PubMed ID: 23133675
[TBL] [Abstract][Full Text] [Related]
11. Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.
Adriaenssens AE; Biggs EK; Darwish T; Tadross J; Sukthankar T; Girish M; Polex-Wolf J; Lam BY; Zvetkova I; Pan W; Chiarugi D; Yeo GSH; Blouet C; Gribble FM; Reimann F
Cell Metab; 2019 Nov; 30(5):987-996.e6. PubMed ID: 31447324
[TBL] [Abstract][Full Text] [Related]
12. GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells.
Shilleh AH; Viloria K; Broichhagen J; Campbell JE; Hodson DJ
Peptides; 2024 May; 175():171179. PubMed ID: 38360354
[TBL] [Abstract][Full Text] [Related]
13. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1.
Hammoud R; Drucker DJ
Nat Rev Endocrinol; 2023 Apr; 19(4):201-216. PubMed ID: 36509857
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
[TBL] [Abstract][Full Text] [Related]
15. Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice.
Leuthardt AS; Boyle CN; Raun K; Lutz TA; John LM; Le Foll C
Eur J Pharmacol; 2023 Sep; 955():175912. PubMed ID: 37454968
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
[TBL] [Abstract][Full Text] [Related]
17. Genetic disruption of the Gipr in Apoe
Pujadas G; Baggio LL; Kaur KD; McLean BA; Cao X; Drucker DJ
Mol Metab; 2022 Nov; 65():101586. PubMed ID: 36055579
[TBL] [Abstract][Full Text] [Related]
18. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
[TBL] [Abstract][Full Text] [Related]
19. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
Campbell JE
Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
[TBL] [Abstract][Full Text] [Related]
20. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
